Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms - Concepedia

Concepedia

Publication | Open Access

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

DOI Full Paper Access

49

Citations

26

References

2018

Year

Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker, Mary‐Elizabeth M. Percival, Paul C. Hendrie, Kelda M. Gardner, Tara L. Chen, Sarah Buckley,

Phase 1/2Hematological MalignancyOncologyHematologyMyeloid NeoplasiaDose-escalated MitoxantronePharmacotherapyMedicineRadiation OncologyRadiologyHealth Sciences

References

	Year	Citations

Page 1

Page 1